{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:24:32Z","timestamp":1785417872349,"version":"3.56.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) have limited effective treatment options. Bruton tyrosine kinase inhibitors (BTKis) increase the anti\u2010tumoural phenotype of tumour\u2010associated macrophages, providing rationale to combine them with rituximab and lenalidomide (R\n                    <jats:sup>2<\/jats:sup>\n                    ). Acalabrutinib, a second\u2010generation BTKi, has potential to improve R\n                    <jats:sup>2<\/jats:sup>\n                    efficacy without increasing T\u2010cell\u2013mediated toxicity due to its lack of interleukin\u20102\u2013inducible T\u2010cell kinase inhibition. Here, we report safety and efficacy from a phase 1b dose\u2010finding study (NCT02180711) evaluating acalabrutinib plus R\n                    <jats:sup>2<\/jats:sup>\n                    in patients with R\/R FL. Overall, 29 patients received acalabrutinib plus R\n                    <jats:sup>2<\/jats:sup>\n                    (lenalidomide 15\u2009mg,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098; lenalidomide 20\u2009mg,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200921). At a median acalabrutinib exposure of 21\u2009months, the most common grade \u22653 treatment\u2010emergent adverse event (TEAE) was neutropenia (37.9%). The incidence of grade \u22653 serious TEAEs was 37.5% and 52.4% in the lenalidomide 15\u2010mg and 20\u2010mg cohorts, respectively; overall, the most common were COVID\u201019 pneumonia, COVID\u201019 infection and pneumonia. Earlier treatment withholdings\/reductions were observed in the 20\u2010mg cohort. With a median follow\u2010up of 34.1\u2009months, the overall response rate was 75.9%. The complete response rate was 25.0% and 42.9% in the lenalidomide 15\u2010 and 20\u2010mg cohorts, respectively. Due to acceptable toxicity and preliminary efficacy, the lenalidomide 20\u2010mg dose was selected for further investigation.\n                  <\/jats:p>","DOI":"10.1111\/bjh.19951","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T19:30:24Z","timestamp":1734031824000},"page":"887-898","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open\u2010label study (\n                    <scp>ACE<\/scp>\n                    \u2010\n                    <scp>LY<\/scp>\n                    \u2010003)"],"prefix":"10.1111","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1459","authenticated-orcid":false,"given":"Paolo","family":"Strati","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richy","family":"Agajanian","sequence":"additional","affiliation":[{"name":"The Oncology Institute of Hope and Innovation  Downey California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center University of Miami\u2013Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[{"name":"Clinical Research Alliance\/Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-7124","authenticated-orcid":false,"given":"Robert","family":"Kridel","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wood","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lesley","sequence":"additional","affiliation":[{"name":"AstraZeneca  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan\u2010Chuan","family":"Wun","sequence":"additional","affiliation":[{"name":"AstraZeneca  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"University of North Carolina Lineberger Cancer Center  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_9_5_1","unstructured":"Revlimid [package insert]. Summit NJ: Celgene; 2021."},{"key":"e_1_2_9_6_1","unstructured":"Lenalidomide Krka d.d. Novo mesto [summary of product characteristics]. European Medicines Agency; 2021."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.03.009"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005722"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007104"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-640805"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-640912"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-718106"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35114"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001116"},{"key":"e_1_2_9_16_1","unstructured":"Calquence [package insert]. Wilmington DE: AstraZeneca Pharmaceuticals; 2022."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11782"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0136-x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003570"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169334"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18368"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19787"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.9258"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0029"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.04.009"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_2_9_29_1","unstructured":"Brukinsa [summary of product characteristics]. Dublin Ireland: BeiGene Ireland; 2024."},{"key":"e_1_2_9_30_1","unstructured":"A Study of Zanubrutinib Plus Anti\u2010CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed\/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) NCT05100862 [Internet]. 2024 [accessed 2024 Aug 16.]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05100862."},{"key":"e_1_2_9_31_1","unstructured":"Yescarta [package insert]. Santa Monica CA: Kite Pharma; 2024."},{"key":"e_1_2_9_32_1","unstructured":"Kymriah [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation; 2024."},{"key":"e_1_2_9_33_1","unstructured":"Lunsumio [package insert]. South San Francisco CA: Genentech Inc.; 2022."},{"key":"e_1_2_9_34_1","unstructured":"Epkinly [package insert]. Plainsboro NJ: Genmab US Inc.; 2024."},{"key":"e_1_2_9_35_1","unstructured":"Tazverik [package insert]. Cambridge MA: Epizyme; 2023."}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19951","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.19951","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:55:07Z","timestamp":1774256107000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/bjh.19951"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19951","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"2024-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}